AbbVie (ABBV) is suing Indian generic drugmaker Sun Pharmaceutical for infringing on its patent...
Friday, January 25, 6:19 PM ETAbbVie (ABBV) is suing Indian generic drugmaker Sun Pharmaceutical for infringing on its patent for Zemplar, a drug used to treat secondary hyperparathyroidism in people with chronic kidney failure. The company asserts that Mumbai-based Sun is preparing to market a low-cost version of the drug prior to its U.S. patent expiry in 2016. View the complaint in its entirety here.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles